Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1140690

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1140690

Global Oncology Therapy Market - 2022-2029

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

Oncology Therapy Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.3% during the forecast period (2022-2029).

Cancer therapies are medications designed to limit cancer growth and proliferation by interfering with specific molecules involved in the growth and expansion of malignant cells, such as proteins or DNA. Cancers of the lung, colorectal, breast, kidney and other organs are common in the population. The stage of disease progression primarily determines cancer treatment. It typically comprises radiotherapy, chemotherapy, surgery, and other cancer therapies. Immunotherapy, targeted therapy, hormone therapy, and stem cell transplant are now being researched and tested in clinical studies.

Market Dynamics

The major driving forces are the rise in cancer incidences, which has led to increased demand for cancer drugs, increased demand for precision medicine, increased number of collaborations between the pharmaceutical companies, increased recent advances in technology, and increased research activities in cancer, increasing geriatric population globally. In addition, the rise in healthcare expenditure worldwide and the rise.

An increase in the number of recent advances in technology and the use of information is expected to drive market growth.

Advanced medical devices, big data, artificial intelligence, and mobile apps drive better patient engagement. Big data has made treatments easier as it provides patient navigation, patient-reported outcomes, identification of high-risk patients, patient satisfaction scoring, and appropriate treatment. AI uses DL algorithms and convolutional neural networks (CNN), which analyze pixel-level information from images in oncology. For instance, the increasing usage of mobile apps in many nations results from technological advancements that can enhance cancer diagnosis, treatment, adherence, and other elements of the patient experience. In addition, Genentech approved a new medicine called Chimeric Antigen Receptor T-cell (CAR-T) therapy to improve CAR-T therapy. The therapy is quite expensive for patients, but an innovative pay-for-performance contract was also revealed in conjunction with the launch of the first CAR-T therapy to make it more accessible.

Furthermore, the new radio-labeled drug sustainability has lowered cancer patients' risk and death rate. The medicine is composed of radioisotope LU attached to octreotide that binds the tumor cells, enables the radiation, and directly targets the cancer cells. Thus, the recent advancements in technology are expected to boost the market.

Restraint:

However, the onset of adverse effects associated with the use of cancer drugs and high costs related to cancer drug development is among a few major factors expected to hamper the growth of the oncology therapy market.

Industry Analysis

The oncology therapy market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Targeted therapy segment is expected to hold the largest market share in the oncology therapy market.

The targeted therapy segment accounted for the largest market share in 2021. The segment benefited due to its fewer side effects offered by the treatment than the conventional therapy and cost-effective nature, and its increased number of dynamics. Moreover, the targeted therapy includes hormone therapies, apoptosis inducers, gene expression modulators, angiogenesis inhibitors, PARP inhibitors, signal transduction inhibitors, and toxin delivery molecules. These drugs inhibit the growth and spread of cancer cells and limit harm to normal cells. In addition, there are increasing FDA approvals in the region. For instance, Trodelvy (sacituzumab govitecan-hziy) was approved by the US Food and Drug Administration in April 2020 for treating adult patients with triple-negative breast cancer. Trodelvy is a drug combination of a Trop-2-directed antibody and a topoisomerase inhibitor that targets the Trop-2 receptor, which aids cancer growth, division, and dissemination. Furthermore, Tabrecta (capmatinib) was authorized by the US FDA in May 2020 to treat adult patients with non-small cell lung cancer (NSCLC), making it the first FDA-approved targeted medication to treat NSCLC with particular mutations. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global oncology therapy market.

North America accounted for the highest revenue share in 2021. The increasing prevalence of cancer, innovations in the cancer therapies, rising clinical trials for the therapies, increasing FDA approvals in the region and product launches by the market players are the factors to drive the market in the forecast period. For instance, For instance, according to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of oncology therapies. Moreover, the FDA approved Amgen's LUMAKRAS (sotorasib) in May 2021 to treat adult patients with KRAS G12C-mutated locally progressed or metastatic non-small cell lung cancer (NSCLC). Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the oncology therapy market are Pfizer, Inc., Novartis, Amgen Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson Others.

Merck & Co Inc.:

Overview:

Merck & Co Inc (Merck) is a biopharmaceutical firm specializing in researching, developing, producing, and marketing prescription medications, biologic therapies, vaccines, and animal health products. It provides prescription medications for cardiovascular, cancer, immunological disorders, infectious, respiratory, and women's diseases, as well as diabetic therapy. The company sells animal health items such as vaccinations, poultry, cattle, and aquaculture products. Merck offers pharmaceuticals to drug wholesalers, retailers, hospitals, government agencies, managed health care providers, and animal health products to veterinarians, distributors, and livestock producers. The company's subsidiaries and affiliates operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

Product Portfolio:

KEYTRUDA (pembrolizumab): KEYTRUDA is a prescription medicine used to treat: a kind of skin cancer called melanoma. It may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

The global oncology therapy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Product Code: DMPH1793

Table of Contents

1. Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the market

2. Key Trends and Developments

  • 2.1. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet By Treatment
  • 3.2. Market Snippet By types DataM CLO Scenario

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence
      • 4.1.1.2. Driver 2
    • 4.1.2. Restraints
      • 4.1.2.1. Onset of adverse effects
      • 4.1.2.2. Restraint 2

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply chain analysis
  • 5.3. Pricing analysis
  • 5.4. Regulatory analysis
  • 5.5. Patent analysis

6. By Treatment

  • 6.1. Introduction
  • 6.2. Market size analysis, and y-o-y growth analysis (%), By Treatment segment
  • 6.3. Market attractiveness index, By Treatment segment
  • 6.4. Targeted therapy
    • 6.4.1. Introduction
    • 6.4.2. Market size analysis, y-o-y growth analysis (%)
  • 6.5. Immunotherapy
    • 6.5.1. Introduction
  • 6.6. Chemotherapy
  • 6.7. Radiation therapy
  • 6.8. Others

7. By Type

  • 7.1. Introduction
  • 7.2. Market size analysis, and y-o-y growth analysis (%), By Type segment
  • 7.3. Market attractiveness index, By Type segment
  • 7.4. Breast cancer
    • 7.4.1. Introduction
    • 7.4.2. Market size analysis, y-o-y growth analysis (%)
  • 7.5. Lung cancer
    • 7.5.1. Introduction
  • 7.6. Blood cancer
  • 7.7. Kidney cancer
  • 7.8. Hematological cancer
  • 7.9. Prostate cancer
  • 7.10. Gastrointestinal cancer
  • 7.11. Gynecologic cancer
  • 7.12. Others

8. By End-users

  • 8.1. Introduction
  • 8.2. Market size analysis, and y-o-y growth analysis (%), By End-users segment
  • 8.3. Market attractiveness index, By End-users segment
  • 8.4. Hospitals
    • 8.4.1. Introduction
    • 8.4.2. Market size analysis, y-o-y growth analysis (%)
  • 8.5. Specialty clinics
    • 8.5.1. Introduction
  • 8.6. Cancer and radiation therapy centers

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key region-specific dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
    • 9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
    • 9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Italy
      • 9.5.6.5. Spain
      • 9.5.6.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
    • 9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
    • 9.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
    • 9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
    • 9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
    • 9.7.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. The Middle East And Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment

10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Comparative type portfolio analysis
  • 11.4. Market positioning/share analysis
  • 11.5. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Pfizer, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio And Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis
  • 12.3. Amgen Inc
  • 12.4. AstraZeneca PLC
  • 12.5. Bayer AG
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. Johnson and Johnson
  • 12.8. Others

13. Premium Insights

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About us and services
  • 14.3. Contact us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!